CHA₂DS₂-VASc score
Authored by Patient infomatics teamOriginally published 8 Feb 2026
Meets Patient’s editorial guidelines
- DownloadDownload
- Share
- Language
- Discussion
- Ask Patient
- Audio Version
- Add to preferred sources on Google
Medical Professionals
Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find one of our health articles more useful.
The CHA₂DS₂-VASc score is a clinical risk stratification tool used to estimate the risk of stroke and systemic embolism in patients with atrial fibrillation (AF). It is widely used to guide decisions about oral anticoagulation.
The score refines earlier risk models by including additional vascular and demographic risk factors and is recommended in UK and international guidelines.
Clinical context and use
CHA₂DS₂-VASc is used in patients with non-valvular atrial fibrillation, including paroxysmal, persistent, and permanent AF.
Its primary purpose is to identify patients who are likely to benefit from anticoagulation in order to reduce the risk of ischaemic stroke. It is typically used alongside bleeding risk assessment and shared decision-making.
The score should be recalculated periodically, as stroke risk increases with age and the development of new comorbidities.
Components of the CHA₂DS₂-VASc score
Points are assigned for the following risk factors:
Congestive heart failure or left ventricular dysfunction: 1 point.
Hypertension, treated or untreated: 1 point.
Age 75 years or older: 2 points.
Diabetes mellitus: 1 point.
Prior stroke, transient ischaemic attack, or systemic embolism: 2 points.
Vascular disease, including previous myocardial infarction, peripheral arterial disease, or aortic plaque: 1 point.
Age 65–74 years: 1 point.
Sex category female: 1 point.
The total score ranges from 0 to 9.
Interpretation of scores
Higher scores indicate a greater annual risk of stroke.
In UK practice, anticoagulation is generally recommended for:
Men with a score of 2 or more.
Women with a score of 3 or more.
Anticoagulation may be considered for:
Men with a score of 1.
Women with a score of 2.
A score of 0 in men, or 1 in women where the only point is sex category, is generally considered low risk and does not usually require anticoagulation.
Decisions should always be individualised and made in the context of patient preference, bleeding risk, and overall clinical picture.
Role in anticoagulation decisions
The CHA₂DS₂-VASc score helps identify patients who are likely to derive net benefit from anticoagulation therapy.
It does not determine the choice of anticoagulant. Selection between direct oral anticoagulants and vitamin K antagonists depends on patient characteristics, contraindications, renal function, drug interactions, and local guidance.
Stroke prevention strategies should be reviewed regularly, particularly after hospital admissions or changes in health status.
Evidence base
CHA₂DS₂-VASc has been validated in large cohort studies and has demonstrated improved discrimination of stroke risk compared with earlier scoring systems.
It is incorporated into NICE, ESC, and other international guidelines for the management of atrial fibrillation.
Limitations and clinical judgement
The score estimates population-level risk and does not predict individual outcomes with certainty.
It does not account for bleeding risk, frailty, or life expectancy, which must also be considered. Bleeding risk assessment tools, such as HAS-BLED, are commonly used alongside CHA₂DS₂-VASc to support balanced decision-making.
The score should not be used in patients with mechanical heart valves or moderate to severe mitral stenosis, where anticoagulation decisions follow different guidance.
Practical use in consultation
Using a recognised scoring system can support consistent prescribing, documentation, and audit. Recording the score also helps structure discussions with patients about stroke risk and the potential benefits and risks of anticoagulation.
Patient picks for Cardiovascular disease

Professional
Nova Biomedical StatStrip ketone test strips: risk of disruption to blood ketone testing due to quality-control failures and supply interruption DSI/2026/013
Nova Biomedical has identified quality issues affecting specified lots of StatStrip ketone test strips. ...ailures and Nova Biomedical has initiated a recall,Read the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for medicines, vaccines and medical devices..
by Medicines and Healthcare products Regulatory Agency (MHRA)

Professional
Coronary artery calcium score
The coronary artery calcium score (CACS) is considered one such tool and i... The presence of calcium in coronary arteries is almost always indicative of atherosclerotic plaque (but bears no relationship to plaque stability or instability). 2021 European Guidelines on cardiovascular disease prevention in clinical practice; European Society of.
by Dr Colin Tidy, MRCGP

Professional
Hypersensitivity vasculitis
Vasculitis Vasculitis is a disorder in which there are inflamed blood vessels. These may include capillaries, arterioles, venules and lymphatics. AAVs are classified according to the... Jennette JC; Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Clin Exp Nephrol. 2013 Oct;17(5):603-6. doi:.
by Dr Colin Tidy, MRCGP

Professional
Physiological changes in pregnancy
Pregnancy changes Pregnancy is associated with normal physiological changes that assist fetal survival as well as preparation for labour. Clin Pharmacokinet. 2012 Jun 1;51(6):365-96. doi: 10.2165/11597440-000000000-00000. 54199 : Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters.
by Dr Hayley Willacy, FRCGP

Professional
Vasculitis
BMC Musculoskelet Disord. 2016 Jul 15;17:285. doi: 10.1186/s12891-016-1127-3. 55182 : The prevalence of giant cell arteritis and polymyalgia rheumatica in a UK primary care population. The Chapel Hill Consensus Conference (CHCC) broadly classified the causes of vasculitis into infective and non-infective and then went on to classify the.
by Dr Colin Tidy, MRCGP
A%2F41/og.png)
Professional
Class 4 Medicines Defect Notification: Fexofenadine Hydrochloride 120mg film-coated tablets, Chanelle Medical Unlimited Company, EL(25)A/41
Chanelle Medical Unlimited Company has informed the MHRA of an error with the European Article Number (EAN) / Global Trade Item Number (GTIN) barcode on certain batches of Fexofenadine Hydrochloride 120mg film-coated tablets. Read the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA).
by Medicines and Healthcare products Regulatory Agency (MHRA)
Exclusive updates for healthcare professionals
Stay informed with the latest clinical updates, professional insights, and evidence-based guidance. The Patient Pro newsletter curates essential content for healthcare professionals—delivered straight to your inbox.
By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.
More in cardiovascular disease
- Atrial septal defect
- Brain natriuretic peptide
- Buerger's disease
- Cardiac tumours
- Chronic pericarditis
- Cyanosis
- Diabetic foot
- Digoxin and the cardiac glycosides
- Endocardial fibroelastosis
- Extrasystoles
- Fallot's tetralogy
- Flying with medical conditions
- Libman-Sacks endocarditis
- Mitral valve prolapse
- Posterior myocardial infarct
- Pulmonary embolism
- Raynaud's disease
- Sarcoidosis
- Stroke prevention
- Sudden cardiac death in young people


